(Reuters) - Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.
Novo Nordisk announced results of its STEPwise™ trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, presented at the American Diabetes Association (AD...
COPENHAGEN (Reuters) - Danish diabetes drug maker Novo Nordisk on Friday defended its pricing of diabetes drugs after facing allegations of pricing collusion by U.S. senators.
(Reuters) - France's Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.
COPENHAGEN (Reuters) - Novo Nordisk's experimental injectable diabetes drug semaglutide reduced cardiovascular risk by 26 percent according to the keenly awaited results of a clinical trial released on Friday.